Drugs / EF-009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04381130 | Sep → Dec 2025 overdue | malignant pancreatic neoplasm | Everfront Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EF-009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04381130 ↗ |
| Route | Other | “implanted surgically” NCT04381130 ↗ |